BRISTOL-MYERS SQUIBB ACQUIRES LIPHA GLUCOPHAGE MARKETING RIGHTS

Executive Summary

BRISTOL-MYERS SQUIBB ACQUIRES LIPHA GLUCOPHAGE MARKETING RIGHTS in the U.S. for the pending product for treatment of non- insulin dependent diabetes mellitus (NIDDM) or Type II diabetes, the company announced April 27. Financial terms of the agreement, which is effective immediately, were not disclosed. In exchange, Lipha gains marketing rights in France to BMS's once-a-day ACE inhibitor fosinopril (Monopril) for the treatment of hypertension and congestive heart failure. The Lyon, France-based company will receive marketing rights to additional unnamed BMS products in Europe at a later date, BMS said.